Page last updated: 2024-11-02

pioglitazone and Schizophrenia

pioglitazone has been researched along with Schizophrenia in 4 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.

Research Excerpts

ExcerptRelevanceReference
"In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks."9.22The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016)
"In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks."5.22The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016)
"Pioglitazone did not increase weight or produce any other significant side-effects."2.78Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. ( Bark, N; Davis, JM; Dwivedi, S; Hu, Q; Jin, H; Li, C; Lohr, J; Mortiere, C; Shekhar, A; Smith, RC, 2013)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sullivan, CR1
Mielnik, CA1
O'Donovan, SM1
Funk, AJ1
Bentea, E1
DePasquale, EA1
Alganem, K1
Wen, Z1
Haroutunian, V1
Katsel, P1
Ramsey, AJ1
Meller, J1
McCullumsmith, RE1
Iranpour, N1
Zandifar, A1
Farokhnia, M1
Goguol, A1
Yekehtaz, H1
Khodaie-Ardakani, MR1
Salehi, B1
Esalatmanesh, S1
Zeionoddini, A1
Mohammadinejad, P1
Zeinoddini, A1
Akhondzadeh, S1
Smith, RC1
Jin, H1
Li, C1
Bark, N1
Shekhar, A1
Dwivedi, S1
Mortiere, C1
Lohr, J1
Hu, Q1
Davis, JM1
Edlinger, M1
Ebenbichler, C1
Rettenbacher, M1
Fleischhacker, WW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function[NCT00231894]Phase 456 participants (Actual)Interventional2005-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

2 Hour Glucose From Glucose Tolerance Test China Sample

difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone-6.82
Placebo-40.72

2 Hour Glucose From Glucose Tolerance Test US Sample

difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone-24.19
Placebo15.19

Change From Baseline in Serum Glucose at 3 Months ( 3 Months -Baseline) China Sample

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone-13.33
Placebo-11.5

Change From Baseline in Serum Glucose at 3 Months (3 Months-baseline) US Sample

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone0.02
Placebo24.20

Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) China Site

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone6.52
Placebo7.72

Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) US Sample

serum high density lipoprotein (HDL) (NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment

Interventionmg/dL (Least Squares Mean)
Piogltiazone4.62
Placebo-2.59

Change From Baseline in Serum Triglycerides at 3 Months ( 3 Months-baseline) US Sample

(NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone-49.65
Placebo30.99

Change From Baseline in Serum Triglycerides at 3 Months (3 Months-baseline) China Sample

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone32.56
Placebo-79.12

Change in RBANS List Recognition Scores at 3 Months (3 Months-baseline) US Sample

The scale is Repeatable Battery for the Assessment to Neuropsychological Status (RBANS). This scale measure cognitive function in patients with schizophrenia. Range for list learning sub-score is 0 to 20 . Higher values indicate better performance. For change score (3 months -baseline) positive values indicate improved performance for this cognitive function and negative values indicate poorer performance on this cognitive function. (NCT00231894)
Timeframe: pre-treatment and 3 months of treatment

InterventionUnits on RBANS scale (Least Squares Mean)
Pioglitazone0.27
Placebo-1.11

Trials

2 trials available for pioglitazone and Schizophrenia

ArticleYear
The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
    Human psychopharmacology, 2016, Volume: 31, Issue:2

    Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female

2016
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
    Schizophrenia research, 2013, Volume: 143, Issue:1

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Antisocial Personality Disorder; Case-Control Stu

2013

Other Studies

2 other studies available for pioglitazone and Schizophrenia

ArticleYear
Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments.
    Molecular neurobiology, 2019, Volume: 56, Issue:6

    Topics: Animals; Cluster Analysis; Down-Regulation; Drug Discovery; Energy Metabolism; Gene Knockdown Techni

2019
Treatment of antipsychotic-associated hyperglycemia with pioglitazone: a case series.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Blood Glucose; Female; Homeostasis; Humans; Hyperglycemia; Hypogl

2007